首页> 外文期刊>Biomarkers >Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms
【24h】

Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms

机译:血清细胞因子和CXCR2:卵巢肿瘤中的潜在肿瘤标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose:The aim was to investigate the systemic levels of cytokines and the expression of the chemokine receptor CXCR2 in circulating neutrophils in patients with non-neoplastic ovarian lesions, benign neoplasia or malignant neoplasia. Materials and methods:Controls and patients with ovarian tumours were pre-operatively compared for the production of cytokines (IL-2, IL-5, IL-6, IL-8, IL-10 and TNF-alpha) by ELISA, and for the expression of the chemokine receptor, CXCR2, in neutrophils, by flow cytometry. Randomly selected patients within the malignant group were re-evaluated for the inflammatory parameters at 30 days after surgery. Results:The serum concentrations of IL-6, IL-8 and IL-10 were significantly higher in the benign and malignant neoplasia than in the control group, and their levels were significantly higher in ovarian cancer patients than in patients with non-neoplastic tumours or benign neoplasia. Treatment reduced IL-8 serum levels but did not affect CXCR2 expression in neutrophils. Cut-off values for IL-6, IL-8, and IL-10 comparing malignant vs. benign neoplasia were 11.3, 71.7, 14.8, and comparing malignant neoplasm vs. non-neoplastic lesions were 7.2, 43.5, 12.3, respectively. Conclusions:Serum IL-6, IL-8, and IL-10 levels, and expression of CXCR2 in circulating neutrophils seem promising for distinguishing ovarian cancer patients from patients with benign tumours.
机译:目的:目的是探讨细胞因子的全身水平和趋化因子受体CXCR2在非肿瘤卵巢病变,良性肿瘤或恶性肿瘤患者中循环中性粒细胞的表达。材料和方法:预先使用ELISA的细胞因子(IL-2,IL-5,IL-6,IL-8,IL-10和TNF-Alpha)对照和卵巢肿瘤的对照和患者进行预先操作性。趋化因子受体,CXCR2,中性粒细胞的表达式流式细胞术。在手术后30天内重新评估恶性组内的患者。结果:良性和恶性肿瘤的IL-6,IL-8和IL-10的血清浓度显着高于对照组,卵巢癌患者的水平显着高于非肿瘤肿瘤患者或良性瘤形成。治疗降低了IL-8血清水平,但不影响中性粒细胞中的CXCR2表达。对恶性对良性瘤形成的IL-6,IL-8和IL-10的截止值为11.3,71.7,14.8,并比较恶性肿瘤与非肿瘤病变分别为7.2,43.5,12.3。结论:血清IL-6,IL-8和IL-10水平和CXCR2在循环中性粒细胞中的表达似乎有望区分卵巢癌患者患者良性肿瘤患者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号